The advent of next-generation sequencing technologies has unveiled a new window into the
heterogeneity of acute myeloid leukemia (AML). In particular, recurrent mutations in …

GATA-1 is a key regulator of hematopoiesis. A balanced ratio of its two isoforms, GATA-1FL
and GATA-1S, contributes to normal hematopoiesis, whereas aberrant expression of GATA …

Background Alternative splicing (AS) of RNA is a fundamental biological process that
shapes protein diversity. Many non-characteristic AS events are involved in the onset and …

To provide biologic insights into mechanisms underlying myelodysplastic syndromes (MDS)
we evaluated the CD34+ marrow cells transcriptome using high-throughput RNA …

TEL-AML1 fusion oncogene (t 12; 21) is the most common chromosomal abnormality in
childhood acute lymphoblastic leukemia (ALL). This translocation is associated with a good …

Introduction: Abnormalities in splicing factors, such as mutations or deregulated expression,
can lead to aberrant splicing of target genes, potentially contributing to the pathogenesis of …

Introduction: Abnormalities in splicing factors, such as mutations or deregulated expression,
can lead to aberrant splicing of target genes, potentially contributing to the pathogenesis of …

High-throughput technologies, ranging from microarrays to NexGen sequencing of RNA and
genomic DNA, have opened new avenues for exploration of the pathobiology of human …

Cancerous inhibitor of PP2A (CIP2A) is a prevalent human oncoprotein that inhibits tumor
suppressor PP2A-B56a. However, CIP2A mRNA and protein variants remain …

Inhibition of tumor suppressor Protein Phosphatase 2A (PP2A) has been denoted as one of
the minimal requirements for malignant transformation of a human cell. In cancer, PP2A …